N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Nykode Therapeutics ASA
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nykode Therapeutics ASA
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Cash Equivalents
$136.5m
CAGR 3-Years
-8%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Cash Equivalents
kr23.4m
CAGR 3-Years
-35%
CAGR 5-Years
-27%
CAGR 10-Years
41%
B
Bergenbio ASA
OSE:BGBIO
Cash Equivalents
kr174.8m
CAGR 3-Years
-30%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Cash Equivalents
kr27.4m
CAGR 3-Years
-1%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Cash Equivalents
kr170m
CAGR 3-Years
-3%
CAGR 5-Years
50%
CAGR 10-Years
7%
T
Thor Medical ASA
OSE:TRMED
Cash Equivalents
kr29.6m
CAGR 3-Years
-60%
CAGR 5-Years
-42%
CAGR 10-Years
-5%
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
918.2m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.181 NOK
Overvaluation 94%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Cash Equivalents?
Cash Equivalents
136.5m USD

Based on the financial report for Jun 30, 2024, Nykode Therapeutics ASA's Cash Equivalents amounts to 136.5m USD.

What is Nykode Therapeutics ASA's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
29%

Over the last year, the Cash Equivalents growth was -21%. The average annual Cash Equivalents growth rates for Nykode Therapeutics ASA have been -8% over the past three years , 29% over the past five years .

Back to Top